Please try another search
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Name | Age | Since | Title |
---|---|---|---|
Xiaohui Ji | 59 | 2020 | Independent Director |
Li Zhu | 72 | 2020 | Non-Independent Director |
Patrick Casey | 65 | 2020 | Independent Director |
Tomas J. Heyman | 66 | 2022 | Independent Director |
Corazon Dating Sanders | 65 | 2020 | Independent Director |
Li Mao | - | 2022 | Independent Director |
Wai Man Yau | 45 | 2020 | Independent Director |
Ye Wang | 54 | 2015 | Director |
Ying Huang | 49 | 2019 | CEO & Director |
Fangliang Zhang | 57 | 2020 | Independent Chairman |
John M. Maraganore | 61 | 2023 | Member of Strategic Advisory Board |
Michel Vounatsos | 61 | 2023 | Member of Strategic Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review